Chipscreen Biosciences
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech pioneer developing original small molecule drugs for oncology and metabolic diseases using chemical genomics and AI platforms.
OncologyMetabolic DiseasesAutoimmune DiseasesCentral Nervous System DiseasesAntiviral
Technology Platform
Integrated drug discovery platform combining chemical genomics for target identification/validation with AI-assisted design for molecular discovery and optimization.
Opportunities
Growth opportunities include expanding indications for marketed drug Chidamide, advancing novel clinical candidates like the PRMT5 inhibitor CS08399 globally, and leveraging AI partnerships to accelerate and diversify the early-stage pipeline.
Risk Factors
Key risks include clinical trial failures for novel pipeline assets, intense competition in core oncology and metabolic markets, and pricing/reimbursement pressures within the Chinese healthcare system.
Competitive Landscape
Competes with other innovative Chinese biotechs (e.g., BeiGene, Zai Lab) and global pharma in oncology. Differentiation lies in its pioneering chemical genomics platform, focus on first-in-class small molecules, and early commercial success with an original HDAC inhibitor.